Aflac
AFL
$124.32
-0.35%
Aflac Inc. is a supplemental health and life insurance provider operating primarily in Japan and the United States, selling cancer, accident, dental, vision, disability, and long-term-care policies through worksite and digital distribution channels. Aflac Japan is the larger of its two reportable segments and the company's historical profit engine, while Aflac U.S. provides a second, dollar-denominated growth pillar; the company is a niche specialist rather than a broad-based multiline carrier, with a brand identity built on the famous duck advertising campaign and a reputation for conservative underwriting and capital return. The current investor debate centers on three issues: the durability of Aflac Japan's earnings given yen volatility and a shrinking Japanese policyholder base, the company's ability to offset that with U.S. supplemental growth, and an emerging AI-efficiency narrative that bulls argue can lower expense ratios while supporting an attractive combined dividend-and-buyback yield. Recent quarterly results have been noisy — headline revenue fell sharply year over year in Q3 2026 — which has kept sentiment cautious even as the stock has quietly outperformed the market over the past three and six months.…
AFL
Aflac
$124.32
Related headlines
Investment Opinion: Should I buy AFL Today?
Rating: Hold. Aflac is a high-quality, low-beta capital-return vehicle whose stock at $127.61 has run roughly 6.5% above the $119.27 analyst average target, with a consensus recommendation of Hold (3.2 mean across 15 analysts: 3 Buy, 8 Hold, 4 Sell) — a setup that offers little margin of safety despite genuine balance-sheet strength. The core thesis is that a fortress balance sheet (debt-to-equity 0.285, current ratio 12.39), a 4.4% free-cash-flow yield on $2.592 billion TTM FCF, and an aggressive buyback (diluted shares down ~6.6% year over year to 496.98 million) support per-share value even while the headline income statement is noisy, but the Q3 2026 revenue decline of 31.75% and net margin collapse to 9.26% mean the earnings trajectory must be proven before paying above consensus.
Supporting evidence is mixed but tilts toward patience rather than accumulation at this price. Valuation is not stretched versus history — 16.07x trailing and 16.47x forward PE, 1.98x price-to-book near its multi-year 2.0x-2.2x average, and a 20.91% net margin with 12.36% ROE that are strong for a life insurer — yet the near-identical trailing and forward multiples imply the market expects flat earnings, and the 3.35x price-to-sales sits above typical carrier levels. Capital return is the clearest support: $803 million of buybacks plus $295 million of dividends in Q3 alone, funded by $1.197 billion of operating cash flow, with a 2.05% dividend yield and a conservative 32.86% payout ratio. Momentum has turned positive (+7.95% in one month versus -2.26% for SPY, a +10.21 point relative strength spread), but the one-year relative strength of -1.31 points shows this is an early inflection, not a confirmed trend, and the stock sits only ~2.8% below its $131.19 52-week high.
Three risks could invalidate the thesis: (1) the Q3 margin compression proves structural rather than a one-off from investment losses or yen translation, pushing EPS below the $8.25 consensus; (2) further yen weakness or Japanese policyholder attrition erodes the $2.156 billion Aflac Japan revenue pool, the largest single profit engine; and (3) valuation compression toward peer multiples given 12 of 15 analysts at Hold or Sell and repeated Underperform/Underweight reiterations from Evercore ISI, Mizuho, and Barclays with no upgrades in the visible history. This Hold would upgrade to Buy on evidence that Q4 margins normalize toward the Q2 2026 level (20.21% net margin) and Japan earnings stabilize, ideally on a pullback toward the $119 average target or the $111-$112 support zone; it would downgrade to Sell on a break below $111 that confirms trend failure or a second consecutive quarter of double-digit revenue decline. Net verdict: fairly valued to modestly overvalued relative to consensus and its own recent history — a defensible income holding, not a compelling new entry at $127.61.
Sign up to view all
AFL 12-Month Price Forecast
Aflac presents a genuinely balanced setup: a fortress balance sheet, dependable capital return, and a low 0.548 beta argue for holding the stock, but a price above consensus fair value, a 3.2 recommendation mean, and a Q3 revenue decline of 31.75% argue against adding at $127.61. The valuation is not stretched versus history — 16.07x trailing PE and 1.98x price-to-book near its multi-year average — but the tight 16.07x trailing to 16.47x forward gap signals the market expects flat earnings, leaving little room for disappointment. The decisive variable is whether Q3's margin collapse to 9.26% was a one-off from investment losses and yen translation or the start of structural erosion; Q2 2026's 20.21% net margin and Q1's 23.62% suggest the former, which is why the stance is neutral rather than bearish. I would upgrade to bullish on a Q4 report showing margin recovery into the high-teens with Japan revenue stabilizing, or on a pullback toward the $119 average target that restores margin of safety; I would downgrade to bearish on a break below the $111-$112 support zone or a second consecutive quarter of double-digit revenue decline.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Aflac's 12-month outlook, with a consensus price target around $119.87 and implied upside of -3.6% versus the current price.
Average Target
$119.87
15 analysts
Implied Upside
-3.6%
vs. current price
Analyst Count
15
covering this stock
Price Range
$101 - $143
Analyst target range
Coverage is broad but the tone is cautious. Fifteen analysts cover Aflac with a distribution of 3 Buy, 8 Hold, and 4 Sell, producing a consensus recommendation of Hold and a recommendation mean of 3.2 (where higher is more bearish). The average target price is $119.27, which implies roughly 6.5% downside from the current $127.61 — a notable signal that the stock has run past consensus fair value. The consensus is therefore neutral-to-bearish, and the recent institutional actions reinforce that: Evercore ISI and Mizuho reiterated Underperform on November 12, Wells Fargo maintained Equal Weight, Barclays reiterated Underweight in October, and only Piper Sandler stands out with an Overweight. There have been no upgrades in the visible ratings history.
The target range of $101.00 to $143.00 is wide — about 33% from low to high — signaling genuine disagreement about the earnings trajectory. The $143 high target implies roughly 12% upside and would require either a re-rating toward 17x-18x forward earnings or evidence that the Q3 revenue decline was transient and that Japan earnings are stabilizing; it likely assumes successful AI-driven expense reduction and continued buyback accretion. The $101 low target implies about 21% downside and prices in margin compression, further yen weakness, or deterioration in the Japanese policyholder base. With the stock trading above the average target and the majority of analysts at Hold or Sell, the setup is one of price momentum running ahead of fundamental conviction — a dynamic that can persist in low-beta dividend names but leaves little margin of safety if the next earnings report disappoints.
Bulls vs Bears: AFL Investment Factors
The bear case currently has stronger near-term evidence: AFL trades 6.5% above the $119.27 consensus target with a 3.2 recommendation mean, 12 of 15 analysts at Hold or Sell, and a Q3 revenue decline of 31.75% alongside a net margin collapse to 9.26%. The bull case rests on capital return mechanics and momentum rather than the income statement — a 6.6% share-count reduction, a 4.4% FCF yield, 0.285 debt-to-equity, and +10.21 points of one-month relative strength — which is real but does not offset a deteriorating top line. The single most important tension is whether Q3's weakness was a one-off from investment losses and yen translation or the start of structural margin erosion; Q1 2026's $1.019 billion net income at a 23.62% margin suggests the core franchise is intact, and resolution of that question at the next earnings report will determine whether the stock re-rates toward the $143 high target or de-rates toward the $101 low.
Bullish
- Momentum inflection with strong relative strength: AFL has gained 7.95% over the past month versus a 2.26% decline for SPY, a +10.21 point relative strength spread, and is up 5.07% over three months against a -2.83% SPY move (+7.90 points). The one-year relative strength is still slightly negative at -1.31 points, which suggests this is an early-stage momentum turn rather than a mature, exhausted trend.
- Aggressive buyback shrinking share count: Diluted shares fell to 496.98 million in Q3 2026 from 532.02 million a year earlier, a roughly 6.6% reduction, after $803 million of buybacks in Q3 alone and $1.0 billion in Q1. This mechanical per-share EPS tailwind is meaningful for a company whose forward PE of 16.47x implies flat headline earnings growth.
- Fortress balance sheet and cash generation: Debt-to-equity is just 0.285, the current ratio is 12.39, and trailing free cash flow is $2.592 billion against a $58.4 billion market cap, a ~4.4% FCF yield. Q3 operating cash flow of $1.197 billion comfortably funded both the buyback and the $295 million dividend.
- Low beta and modest drawdown support sizing: Beta of 0.548 means AFL moves roughly 45% less than the market, and the maximum drawdown over the period was only -14.18%. For income and risk-averse portfolios, that volatility profile supports larger position sizing and makes the 2.05% dividend yield with a 32.86% payout ratio more dependable.
Bearish
- Price above consensus target: At $127.61, AFL trades above the $119.27 average analyst target, implying roughly 6.5% downside to consensus fair value. With 8 Hold and 4 Sell ratings against only 3 Buys and a recommendation mean of 3.2, the stock has run past the Street's fundamental conviction.
- Q3 revenue collapse and margin compression: Q3 2026 revenue fell 31.75% year over year to $3.271 billion from $4.793 billion, and net income dropped to $303 million (9.26% margin) from $1.639 billion (34.20% margin). The operating margin collapsed to 15.29% from 41.60%, and the quarterly revenue sequence has deteriorated from $4.315 billion in Q1 to $3.271 billion in Q3.
- Japan concentration and yen translation risk: Aflac Japan generated $2.156 billion of revenue versus $1.781 billion for Aflac U.S., making Japan the largest single revenue pool and the largest source of currency and policy-persistence risk. Consensus 2027 revenue of roughly $17.44 billion implies only stabilization, not recovery, so the top line offers no cushion.
- No analyst upgrades and persistent Underweight calls: Evercore ISI and Mizuho reiterated Underperform on November 12, Barclays reiterated Underweight in October, and Wells Fargo maintained Equal Weight, with no upgrades in the visible ratings history. The $101 low target implies about 21% downside and prices in margin compression and further yen weakness.
AFL Technical Analysis
Aflac is in a sustained, orderly uptrend. The stock is up 10.96% over the past year, 15.76% year to date, and 9.25% over six months, and at $127.61 it sits at roughly 85.8% of its 52-week range of $105.76 to $131.19 — near the upper end but not yet at the highs. That positioning is characteristic of a healthy trend with room to run rather than a blow-off top, though it does mean the easy money from the 2026 lows has already been made and the risk/reward for new entries is less asymmetric than it was in the spring. The 52-week high of $131.19 is only about 2.8% above the current price, so the stock is effectively testing resistance now.
Short-term momentum is clearly accelerating and, importantly, is diverging positively from the longer-term trend. The stock gained 7.95% in the past month versus a 2.26% decline for SPY, producing a relative strength of +10.21 percentage points, and it added 5.07% over three months against a 2.83% SPY decline (+7.90 points of relative strength). The one-year relative strength is slightly negative at -1.31 points, meaning the stock has only recently begun to outperform after roughly a year of market-lagging performance — a classic momentum inflection rather than a mature trend. Volume data is unavailable (reported as zero), so price action alone must carry the signal, and the pattern of higher lows from the late-September trough near $111.18 to the current $127.61 supports the bullish read.
Key technical levels are well defined. Support sits at the 52-week low of $105.76, with a nearer intermediate floor around the $111-$112 area that marked the September-October base; resistance is the 52-week high of $131.19, roughly 2.8% above the current price. A decisive breakout above $131.19 would confirm the multi-month uptrend and likely invite momentum and dividend-oriented buyers, while a breakdown below $111 would break the sequence of higher lows and signal trend failure. Volatility is low: beta of 0.548 means the stock moves roughly 45% less than the market, and the maximum drawdown of -14.18% over the period is modest for an equity — supportive of larger position sizing for risk-averse or income-focused portfolios, but also implying the stock will lag in strong risk-on rallies.
Beta
0.55
0.55x market volatility
Max Drawdown
-14.2%
Largest decline past year
52-Week Range
$106-$131
Price range past year
Annual Return
+12.5%
Cumulative gain past year
| Period | AFL Return | S&P 500 |
|---|---|---|
| 1m | +3.5% | -9.7% |
| 3m | +7.1% | -9.9% |
| 6m | +5.5% | -7.5% |
| 1y | +12.5% | +4.7% |
| ytd | +12.8% | +1.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AFL Fundamental Analysis
The revenue picture is the weakest part of the Aflac story and requires careful interpretation. Q3 2026 revenue was $3.271 billion, down 31.75% year over year from $4.793 billion in Q3 2025, and the quarterly sequence has deteriorated — $4.315 billion in Q1 2026, $4.083 billion in Q2, then $3.271 billion in Q3 — a pattern that partly reflects volatile net investment gains and yen translation rather than pure premium deterioration, but the headline trend is nonetheless negative. Segment data shows Aflac Japan at $2.156 billion and Aflac U.S. at $1.781 billion, with other segments at $360 million, confirming Japan remains the largest single revenue pool and therefore the largest source of translation and policy-persistence risk. Consensus 2027 revenue of roughly $17.44 billion implies stabilization rather than recovery, so the investment case rests more on earnings quality and capital return than on top-line growth.
Profitability remains solid but is compressing at the margin. Q3 2026 net income was $303 million on a 9.26% net margin, down sharply from $1.639 billion and a 34.20% net margin in Q3 2025, while gross margin fell to 56.01% from 43.90% a year earlier — the gross margin move is actually favorable, but the operating margin collapsed to 15.29% from 41.60% as the prior-year quarter benefited from unusual items. The trailing operating margin of 26.61% and net margin of 20.91% remain respectable for a life insurer, and the Q2 2026 quarter showed the underlying earning power with $825 million of net income on a 20.21% net margin. The key question is whether Q3's weakness is a one-off (investment losses, yen, or reserve adjustments) or the start of structural margin erosion — the Q1 2026 result of $1.019 billion net income and 23.62% margin suggests the core franchise is intact.
Balance sheet and cash generation are strong, which underpins the dividend and buyback story. Debt-to-equity is just 0.285, the current ratio is an unusually high 12.39, and trailing free cash flow is $2.592 billion against a $58.4 billion market cap — a free cash flow yield of roughly 4.4%. ROE is 12.36% and ROA 2.41%, modest in absolute terms but normal for a life insurer with a large investment portfolio. The company returned capital aggressively in 2026: $803 million of buybacks and $295 million of dividends in Q3 alone, and $1.0 billion of buybacks in Q1, funded comfortably by operating cash flow of $1.197 billion in Q3. The dividend yield of 2.05% with a payout ratio of 32.86% leaves ample room for continued increases, and the shrinking share count (496.98 million diluted in Q3 2026 versus 532.02 million a year earlier) is a meaningful per-share earnings tailwind.
Quarterly Revenue
$3.3B
2026-09
Revenue YoY Growth
-31.8%
YoY Comparison
Gross Margin
56.0%
Latest Quarter
Free Cash Flow
$2.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AFL Overvalued?
Because Aflac is profitable (Q3 2026 net income of $303 million), the PE ratio is the appropriate primary metric. The stock trades at 16.07x trailing earnings and 16.47x forward earnings — an unusually tight gap that implies the market expects essentially flat earnings growth over the next twelve months, consistent with consensus EPS of $8.25 versus the current run-rate. The PEG ratio of -0.55 is not meaningful given negative or distorted growth inputs, and the 3.35x price-to-sales ratio is elevated for an insurer but reflects the investment-income-heavy revenue base. The near-identical trailing and forward multiples suggest the market is pricing Aflac as a mature, low-growth cash-return vehicle rather than a growth story.
Relative to the life insurance industry, Aflac screens cheap on earnings but not on book value. A trailing PE of 16.07x is roughly in line with or slightly below the typical 12x-16x range for large-cap life insurers, while the 1.98x price-to-book is at the higher end for the sector and the 3.35x price-to-sales is well above typical carrier levels. The 10.90x EV/EBITDA is moderate. The premium on book and sales is arguably justified by Aflac's 20.91% net margin and 12.36% ROE, which are strong for the industry, and by its differentiated supplemental-health niche and Japan franchise — but the discount on earnings suggests the market is skeptical about earnings durability given yen exposure and the Q3 revenue decline.
Historically, Aflac's valuation is in the middle-to-upper part of its own range. Trailing PE has ranged from roughly 6.4x-10.6x in 2022-2025 to 45.8x in the distorted Q3 2026 print, and the current 16.07x sits above the 10.60x recorded at year-end 2025 and the 13.78x in Q1 2026. Price-to-book of 1.98x is close to its multi-year average of roughly 2.0x-2.2x, having been as low as 1.16x in late 2021 and as high as 2.51x in Q3 2024. The read-through is that the market is pricing in modestly optimistic expectations relative to the depressed 2025 multiples, but the stock is not stretched versus its own history — leaving room for re-rating if earnings stabilize.
PE
16.1x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 5x~24x
vs. Industry Avg
11.7x
Industry PE ~11.7x*
EV/EBITDA
10.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on earnings volatility and revenue concentration. Q3 2026 revenue fell 31.75% year over year to $3.271 billion while net income dropped to $303 million from $1.639 billion, cutting the net margin to 9.26% from 34.20% and the operating margin to 15.29% from 41.60%. Aflac Japan at $2.156 billion of revenue remains the largest single pool, so yen translation and Japanese policyholder attrition directly hit both the top line and reported earnings. The forward PE of 16.47x versus trailing 16.07x implies the market expects flat earnings, leaving little buffer if the Q3 weakness proves structural rather than a one-off from investment losses or reserve adjustments. Balance-sheet risk is low — debt-to-equity of 0.285 and a current ratio of 12.39 — but the 32.86% payout ratio and heavy buyback program depend on the $2.592 billion FCF stream holding up.
Market and competitive risks are dominated by valuation compression and negative analyst sentiment. The stock trades above the $119.27 average target with a 3.2 recommendation mean, and Evercore ISI, Mizuho, and Barclays have all reiterated Underperform or Underweight calls with no upgrades in the visible history. A 1.98x price-to-book is at the high end for life insurers and a 3.35x price-to-sales is well above typical carrier levels, so any re-rating toward peer multiples would be painful. Beta of 0.548 cushions market-wide selloffs but also means AFL lags in risk-on rotations, and the 5.61 short ratio indicates meaningful bearish positioning. The AI-efficiency narrative that bulls cite as an expense-ratio lever is unproven and could be offset by Japanese regulatory or product-repricing pressure.
Worst-case scenario: yen weakness accelerates, Japanese policyholder lapse rates rise, and the Q3 margin compression proves structural rather than one-off, forcing analysts to cut EPS estimates below the $8.25 consensus and the stock to de-rate toward the $101 low target. From $127.61, that is roughly -21%, and a full retest of the 52-week low of $105.76 would be about -17%. A more severe outcome combining a broad market drawdown with an earnings miss could approach the historical max drawdown of -14.18% from the recent high near $131.19, though the low beta of 0.548 limits the tail. Realistically, an investor should underwrite a -17% to -21% downside scenario over twelve months if the Japan earnings stabilization thesis fails.
FAQ
The most severe risk is earnings durability: Q3 2026 net income fell to $303 million (9.26% margin) from $1.639 billion (34.20% margin) a year earlier, and if that compression proves structural rather than a one-off from investment losses or yen translation, EPS could fall below the $8.25 consensus. Second is Japan concentration and currency risk — Aflac Japan generated $2.156 billion of revenue versus $1.781 billion for the U.S., so further yen depreciation or rising policyholder lapse rates directly hit the largest profit pool. Third is valuation and sentiment risk: with 12 of 15 analysts at Hold or Sell and repeated Underperform/Underweight reiterations from Evercore ISI, Mizuho, and Barclays, a re-rating toward peer life-insurer multiples could compress the 1.98x price-to-book. Fourth is company-specific execution risk around the unproven AI-efficiency narrative and the sustainability of the $803 million quarterly buyback pace, which depends on the $2.592 billion FCF stream holding up.
The 12-month outlook is split into three scenarios. The base case (50% probability) targets $115-$125, assuming Q4 2026 confirms Q3 was largely a one-off, net margin recovers into the high-teens, and Japan revenue holds near $2.1-$2.2 billion per quarter — consistent with the $119.27 average analyst target. The bull case (25% probability) targets $135-$143, requiring margin recovery toward the Q2 2026 level of 20.21%, yen stabilization, continued buybacks, and at least one analyst upgrade toward the $143 high target. The bear case (25% probability) targets $101-$111, driven by a second consecutive quarter of double-digit revenue decline, further yen weakness, and de-rating toward the $101 low target. The base case is most likely, anchored on the assumption that Q3's 9.26% net margin was distorted by investment losses and currency translation rather than structural underwriting deterioration.
AFL screens roughly fairly valued to modestly overvalued. The stock trades at 16.07x trailing and 16.47x forward earnings — an unusually tight gap that implies the market expects flat earnings growth, consistent with the $8.25 consensus EPS. Price-to-book of 1.98x is near its multi-year average of roughly 2.0x-2.2x, while the 3.35x price-to-sales and 10.90x EV/EBITDA are moderate-to-elevated for a life insurer. Relative to the $119.27 average analyst target, the stock at $127.61 is about 6.5% above consensus fair value, which is the clearest signal of overvaluation. The market appears to be paying a modest premium for Aflac's 20.91% net margin, 12.36% ROE, and differentiated Japan supplemental-health franchise, but is unwilling to pay for growth given the negative revenue trend. Net read: not stretched versus its own history, but not a discount either.
From a risk/reward standpoint, AFL is a reasonable hold but a mediocre fresh entry at $127.61. The stock trades about 6.5% above the $119.27 analyst average target, with 12 of 15 analysts rated Hold or Sell and a 3.2 recommendation mean, meaning the market has already priced in much of the near-term good news. The upside case is capped near the $143 high target (about 12% upside), while the downside to the $101 low target is roughly 21%, so the asymmetry is unfavorable at current levels. The strongest supporting evidence is defensive: a 4.4% FCF yield, a 2.05% dividend with a 32.86% payout ratio, and a 6.6% year-over-year reduction in diluted shares. It is a good buy primarily for income-focused, risk-averse investors on a pullback toward the $119 average target or the $111-$112 support zone, and less attractive for growth-oriented buyers.
AFL is better suited to a long-term, income-oriented holding period of at least two to three years than to short-term trading. Its beta of 0.548 and modest -14.18% maximum drawdown make it a low-volatility compounder rather than a momentum vehicle, and the return stream depends on dividend collection (2.05% yield) plus buyback-driven per-share accretion (diluted shares down 6.6% year over year) rather than on rapid price appreciation. Earnings visibility is moderate but noisy — quarterly net income has swung from $29 million in Q1 2025 to $1.639 billion in Q3 2025 to $303 million in Q3 2026 — so short-term traders face headline risk around each earnings report without commensurate volatility to trade. The recent +10.21 point one-month relative strength versus SPY suggests an early momentum turn, but the -1.31 point one-year relative strength shows the trend is not yet confirmed. A minimum holding period of two to three years allows the capital-return engine to compound and gives time for the Japan earnings stabilization thesis to play out.

